Predicting cognitive decline using neuropsychiatric symptoms in prodromal Lewy body disease.
Objective: To investigate the influence of neuropsychiatric symptoms (NPS) on early cognitive decline in patients with Lewy body disease (LBD). Background: NPS in LBD, including…Association between longitudinal degeneration of the cholinergic basal forebrain and cognition-relevant cortical areas in early-stage PD
Objective: To examine whether the association between longitudinal cBF degeneration and cognitive decline in PD is mediated by parallel atrophy of cortical areas. Background: Degeneration…New-onset Parkinsonism after Covid-19: is there a link? A 2022 report of clinical cases
Objective: To document the phenotypic range and nature of all published cases of new-onset parkinsonism developing with or shortly after a reported Severe Acute Respiratory…Parkinson’s disease symptom asymmetry at disease onset corresponds to low-beta power asymmetry in the subthalamic nucleus
Objective: Compare beta-power in the subthalamic nucleus (STN) between the most affected and least affected body side at disease onset. Background: Exaggerated beta activity (13–35…Cholinergic Nucleus 4 Degeneration and Cognitive Impairment in REM Sleep Behavior Disorder
Objective: To determine if there is evidence of cholinergic basal forebrain degeneration, i.e., reduced cholinergic nucleus 4 (Ch4) volume on MRI, in patients with REM…Therapeutic potential of luteolin in manganese induced Parkinson’s disease: Targeting neuroinflammation and oxidative stress.
Objective: To investigate the neurodegenerative facets of Manganese (Mn) in rat model in rat model of Parkinson's disease.To study the neuroprotective effect of luteolin in…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.